Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer

Authors:

Abstract
Tissue-based multigene panel (genomic) tests have been developed and are commercially available for patients with several forms of cancer, including breast, melanoma, and prostate.1-4 Although a range of prognostic tests assess distinct cancer types and underlying pathways, they share a common goal of personalizing decision-making, often modifying the necessity or intensity of treatment based on an individual’s risk. These tests have been particularly promising for the management of prostate cancer, where the aggressiveness of the disease varies considerably among men with localized cancers.5 In retrospective studies, several multigene panels for prostate cancer have been shown to add independent prognostic information beyond standard clinical variables, such as prostate-specific antigen (PSA) level, Gleason score, or clinical stage.6 Although it has been assumed that genomic tests will enhance the precision with which the disease is managed (ie, increased active surveillance for nonaggressive cancers and timely treatment for those with aggressive disease), the effectiveness of testing has not been independently established.7-9 Nevertheless, genomic tests have recently become incorporated into major clinical practice guidelines, such as those from the National Comprehensive Cancer Network, and are covered by most major insurance carriers, including Medicare.

This publication has 39 references indexed in Scilit: